International Medical Journal, Vol. 24., Iss. 2, 2018, P. 49−52.
IMMUNOHISTOCHEMICAL FACTORS OF ENDOMETRIAL CANCER PROGNOSIS
S. P. Grygoriev Institute for Medical Radiology, NAMS of Ukraine, Kharkiv, Ukraine
In the structure of malignant tumors in women, endometrial cancer takes the 3rd place, and the growth rate of morbidity is much higher than that in other malignant tumors of the reproductive system. The recent researches show that there are both morphological and immunohistochemical criteria, the part of the spectrum of which is the study of the proliferative activity of cells in hyperplastic processes, atypical hyperplasia and adenocarcinomas as well as hormone dependence, which accompanies progression of these processes. Because of the frequent concomitant pathology, emergence of hormone dependence of endometrial cancer, it is necessary to search for the new ways to solve the problem of etiology and pathogenesis of this disease, the regularities of its development to provide a reliable diagnosis and optimal treatment. To date, a wide range of markers reflecting different manifestations of the biological aggressiveness of the tumors are available. But the group of immunohistochemical markers that characterize the metabolism of endometrial adenocarcinoma (proteins, enzymes, hormone receptors, angiogenesis, apoptosis, proliferative activity, adhesion molecules, proliferative activity, etc.) has not been identified. As the markers of proliferation and apoptosis are directly related to malignant tumors, the research results can be used in the selection of optimal treatment regimens and evaluating the prediction of endometrial cancer in different clinical stages of the disease.
Key words: endometrial cancer, molecular−biological markers, apoptosis, proliferation, angiogenesis.